Get the Stockscreener App
1.69
9.74%
0.15
After Hours:
1.61
-0.08
-4.73%
Pyxis Oncology Inc stock is traded at $1.69, with a volume of 1.76M.
It is up +9.74% in the last 24 hours and down -55.76% over the past month.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
See More
Previous Close:
$1.54
Open:
$1.54
24h Volume:
1.76M
Relative Volume:
1.47
Market Cap:
$100.50M
Revenue:
-
Net Income/Loss:
$-73.79M
P/E Ratio:
-0.5951
EPS:
-2.84
Net Cash Flow:
$-77.44M
1W Performance:
+4.32%
1M Performance:
-55.76%
6M Performance:
-50.00%
1Y Performance:
-2.87%
1-Day Range:
$1.51
$1.695
1-Week Range:
$1.49
$1.71
52-Week Range:
$1.49
$6.85
Pyxis Oncology Inc Stock (PYXS) Company Profile
Name
Pyxis Oncology Inc
Sector
Industry
Phone
(617) 221-9059
Address
321 HARRISON AVENUE, BOSTON
Compare PYXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.69 | 100.50M | 0 | -73.79M | -77.44M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-21-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-08-24 | Initiated | Stephens | Overweight |
| Aug-08-24 | Initiated | Stifel | Buy |
| May-07-24 | Resumed | Jefferies | Buy |
| Feb-09-24 | Initiated | BTIG Research | Buy |
| Jan-23-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-02-21 | Initiated | BofA Securities | Neutral |
| Nov-02-21 | Initiated | Credit Suisse | Outperform |
| Nov-02-21 | Initiated | Jefferies | Buy |
View All
Pyxis Oncology Inc Stock (PYXS) Latest News
Pyxis Oncology price target lowered to $8 from $10 at RBC Capital - Yahoo Finance
Pyxis Oncology shares target cut, outperform rating on pipeline update By Investing.com - Investing.com Australia
Pyxis Oncology shares target cut, outperform rating on pipeline update - Investing.com
Pyxis Oncology's (PYXS) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move - Benzinga
Royal Bank of Canada Reaffirms Outperform Rating for Pyxis Oncology (NASDAQ:PYXS) - MarketBeat
Pyxis Oncology to Focus on PYX-201, Suspends PYX-106 Program - MarketWatch
Pyxis Oncology advances lead cancer drug PYX-201 - Investing.com
Pyxis Oncology to prioritize PYX-201, suspends investment in PYX-106 - TipRanks
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201 - The Manila Times
Pyxis Oncology, Inc. Announces Portfolio Prioritization, Focusing Resources on Its Lead Clinical Program, PYX-201 - Marketscreener.com
Pyxis Oncology stock hits 52-week low at $1.5 amid market challenges - Investing.com Canada
Pyxis Oncology's SWOT analysis: ADC developer's stock shows promise amid trials - Investing.com Canada
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $10.00 Average Price Target from Brokerages - MarketBeat
Pyxis Oncology stock hits 52-week low at $1.64 - Investing.com
Pyxis Oncology stock hits 52-week low at $1.64 By Investing.com - Investing.com UK
Jacobs Levy Equity Management Inc. Makes New Investment in Pyxis Oncology, Inc. (NASDAQ:PYXS) - MarketBeat
14,897 Shares in Pyxis Oncology, Inc. (NASDAQ:PYXS) Bought by Intech Investment Management LLC - Defense World
Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead (NASDAQ:PYXS) - Seeking Alpha
CFO & COO of Pyxis Oncology Pamela Connealy Buys 13% More Shares - Yahoo Finance
Pyxis Oncology CFO acquires shares worth $174,364 - Investing.com India
Pyxis Oncology CFO acquires shares worth $174,364 By Investing.com - Investing.com South Africa
Institutional owners may ignore Pyxis Oncology, Inc.'s (NASDAQ:PYXS) recent US$142m market cap decline as longer-term profits stay in the green - Yahoo Finance
Pressure on Pyxis despite promising PYX-201 data - The Pharma Letter
Pyxis Oncology's SWOT analysis: ADC innovator's stock poised for growth - Investing.com
Pyxis Oncology's SWOT analysis: ADC innovator's stock poised for growth By Investing.com - Investing.com UK
Pyxis Oncology (NASDAQ:PYXS) Downgraded by William Blair to “Market Perform” - Defense World
Royal Bank of Canada Boosts Pyxis Oncology (NASDAQ:PYXS) Price Target to $10.00 - Defense World
Pyxis Oncology’s (PYXS) Buy Rating Reaffirmed at HC Wainwright - Defense World
William Blair Downgrades Pyxis Oncology (PYXS) - MSN
Pyxis stock craters 46% amid Phase 1 data, William Blair downgrade - MSN
Stock market news: Perspective Therapeutics -44.33%, Pyxis Oncology -42.93% among top losers during mid day trading - Business Upturn
Pyxis stock craters 46% amid Phase 1 data, William Blair downgrade (NASDAQ:PYXS) - Seeking Alpha
Stock market today: Pyxis Oncology plunges by 47.25% while Perspective Therapeutics declines by 46.68% in early trading - Business Upturn
Stock market today: SCWorx Corp. gains 141.81% while Pyxis Oncology down by 46.41% in early trading - Business Upturn
Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns - Benzinga
Pyxis Oncology (NASDAQ:PYXS) Rating Lowered to Market Perform at William Blair - MarketBeat
Pyxis Oncology (NASDAQ:PYXS) Earns Buy Rating from HC Wainwright - MarketBeat
PYXS shares target upgraded, outperform on positive trial data - Investing.com
Institutional investors in Pyxis Oncology, Inc. (NASDAQ:PYXS) lost 11% last week but have reaped the benefits of longer-term growth - Simply Wall St
Pyxis Oncology plummets 38% on preliminary phase 1 data for cancer asset - MSN
Pyxis Oncology Reports Promising Phase 1 Trial Results - TipRanks
Pyxis Oncology announces preliminary PYX-201 data, collaboration with Merck - TipRanks
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data - The Manila Times
Pyxis Oncology, Inc. Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data - Marketscreener.com
Stephens & Co. Initiates Coverage of Pyxis Oncology (PYXS) with Overweight Recommendation - MSN
EPOCH 47: BIOTECH MARKET RESEARCH $PYXS - substack.com
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $9.57 Consensus Target Price from Analysts - MarketBeat
Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Up 19.3% in October - MarketBeat
Pyxis Oncology FY2024 EPS Forecast Lowered by HC Wainwright - MarketBeat
Pyxis Oncology Inc Stock (PYXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):